CTI Biopharma Corp expected to post a loss of 10 cents a share - Earnings Preview

CTI Biopharma

04/03/2023 24:03

* CTI Biopharma Corp  CTIC.OQ   CTIC.O  is expected to show
a rise
in quarterly revenue when it reports  results 
    * The Seattle Washington-based  company is expected to
report
revenue of $23.499 million, according to the mean estimate from
9 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for CTI Biopharma Corp
is for
a loss of 10 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CTI
Biopharma
Corp is $10​, above​ its last closing price of $5.38. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.16       -0.16      -0.13     Beat    17
 Jun. 30 2022  -0.20       -0.20      -0.21     Missed  -4.3
 Mar. 31 2022  -0.45       -0.41      -0.37     Beat    10.6​
 Dec. 31 2021  -0.28       -0.28      -0.38     Missed  -34.9
 ​​Sep.        -0.22       -0.25      -0.26     Missed  -4.7
 30 2021                                                
 Jun. 30 2021  -0.21       -0.21      -0.21     Met     0​
 Mar. 31 2021  -0.22       -0.22      -0.23     Missed  -5.7
 Dec. 31 2020              -0.16      -0.20     Missed  -27
 This summary was machine generated March 4 at 00:03 GMT.  All
figures in US dollars  unless otherwise stated